Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus DERMA SMOOTHE FS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus DERMA SMOOTHE FS.
ALA-SCALP vs DERMA-SMOOTHE/FS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Topical application of a 5% solution to the scalp twice daily.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid